Robert Glanzman, MD

“We took those people who had EDSS of 1.5 or less at baseline…and used their baseline values to compare with the entire population over time. When you take the entire population, of course, at baseline, is worse off than the mildly affected population. But, if you look over time…the population as a whole is improving.”

Clene Nanomedicine recently presented 2 posters from the VISIONARY-MS and REPAIR-MS clinical trials of its investigational nanocatalyst agent, CNM-Au8, which suggest that the therapy can improve the levels of NAD+/NADH (nicotinamide adenine dinucleotide) ratio and AT (adenosine triphosphate) levels, as well as scores on a number of MS Functional Composite subscales measuring visual acuity and neurological status.

The VISIONARY-MS interim data showed that the change in the 6-component composite z-score—which included the SDMT, LCLA in both eyes, 9HPT with both dominant and nondominant hands, and T25W—was significantly improved for those with EDSS 2.0 or higher compared to those with EDSS 1.0 or lower (

 The data were presented virtually at the 

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

, February 25-27, by Robert Glanzman, MD, FAAN, chief medical officer, Clene Nanomedicine.

To find out more about the data and what they imply for the clinical community as CNM-Au8 progresses in its clinical development, 

 caught up with Glanzman in an interview. He offered his insight into the data and his excitement about the novel therapeutic category this agent represents.

For more coverage of ACTRIMS Forum 2021, 

REFERENCES
1. Glanzman RL, Rin J, Greenberg B, et al. Effects of Nanocatalysis on CNS Bioenergetic Markers in Patients Treated with CNM-Au8: Interim Results from Two Phase 231Phosphorous Imaging Studies. Presented at ACTRIMS Annual Forum; February 25-27, 2021. Abstract P043.
2. Glanzman RL, Beadnall H, Barnett M, et al. VISIONARY-MS: Update to a Phase 2 clinical trial of catalytic gold nanocrystals, CNM-Au8, for the treatment of chronic optic neuropathy. Presented at ACTRIMS Annual Forum; February 25-27, 2021. Abstract P050.

Videos

The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.

CNM-Au8 as a Novel Therapeutic Category in MS: Robert Glanzman, MD

“For us, what we’re doing is we’re either donating or receiving electrons directly within cells to drive bioenergetic reactions—the formation of energy within the cell.”

Clene Nanomedicine’s investigational agent, CNM-Au8, has set itself apart from other pipeline products by showing a reduction of neurodegeneration in animal models of diseases like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). No other approved therapies for the treatment of MS have been shown to remyelinate chronic MS lesions, and similarly, no therapies have been shown to slow disease progression across MS, Parkinson disease (PD), nor ALS.

CNM-Au8 is absorbed in the blood stream and dispersed throughout the organ system. Robert Glanzman, MD, chief medical officer, Clene Nanomedicine, described the distinct nanosized crystalized formula as a “bioenergetic catalyst support,” aiming to reduce reaction energy and push other reactions forward.

To find out more about CNM-Au8 and its unique development background, 

 sat down with Glanzman at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum, February 27-29, 2020, in West Palm Beach, Florida. He detailed the reparative and protective characteristics of the drug.

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases. 

Robert Glanzman, MD

Articles

CNM-Au8 as a Novel Therapeutic Category in MS: Robert Glanzman, MD

Robert Glanzman, MD: Overview of CNM-Au8

Latest News